Group 1 - The company has decided to cancel the repurchased A-shares and reduce its registered capital due to not utilizing all repurchased shares for employee stock ownership plans or equity incentives within the stipulated three-year period [2][4] - The total number of shares will decrease from 247,449,899 to 247,043,801, with A-shares reducing from 114,778,999 to 114,372,901 [2] - The registered capital will be reduced from RMB 247,449,899 to RMB 247,043,801 following the cancellation of 406,098 shares [2] Group 2 - The company held its first extraordinary general meeting of shareholders on October 23, 2025, where the resolution for the cancellation of repurchased shares was approved [10][14] - The meeting was conducted in compliance with the relevant laws and regulations, with all directors present [10][15] - All resolutions, including the one regarding the cancellation of repurchased shares, were passed with more than two-thirds of the voting rights held by attending shareholders [14]
康希诺生物股份公司关于注销回购A股股份并减少注册资本暨通知债权人的公告